A Preoperative Window-of-opportunity Study of Imlunestrant in Estrogen Receptor-Positive, HER2-negative Early Breast Cancer: Results from the EMBER-2 Study

Patrick Neven, Nicole Stahl,Maria Vidal,Miguel Martin, Nadia Harbeck,Peter A. Kaufman,Francois-Clement Bidard, Peter A. Fasching,Philippe Aftimos,Erika Hamilton,Stacey Carter,Peter Schmid,Duncan Wheatley,Manali Bhave,Kelly K. Hunt,Swati A. Kulkarni,Roohi Ismail-Khan,Claudia Karacsonyi,Shawn T. Estrem,Umut Ozbek,Bastien Nguyen,Eva Ciruelos

Senologie（2023）

引用 0|浏览20

暂无评分

摘要

Objective Imlunestrant is a novel, orally bioavailable selective estrogen receptor degrader. We present pharmacodynamic (PD) data from the preoperative window-of-opportunity study (EMBER-2), evaluating imlunestrant monotherapy in ER+, HER2− early breast cancer (EBC).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要